[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations].

Objective: To investigate the clinical characteristics and influence of co-mutated gene on acute myeloid leukemia patients (AML) with FMS-like tyrosine kinase-3 (FLT3) mutations.

Methods: A total of 273 FLT3⁺ AML patients were enrolled, and the co-mutation gene data of the patients were collected to further analyze the prognosis of the patients. FLT3 and other common mutations were quantified by PCR amplification products direct sequencing and second-generation sequencing (NGS).

Results: When patients were divided into FLT3- ITD ⁺, FLT3- TKD ⁺, FLT3- ITD ⁺+TKD ⁺ and FLT3- ITD ^-+TKD ^- group according to the type of FLT3 mutations, it was found that the frequencies of TET2, GATA2, NRAS and ASXL1 mutation were significantly different among the 4 groups (all P < 0.05). When patients were divided into allelic ratio (AR) ≥0.5 and <0.5 group, it was found that the frequencies of FLT3- ITD ⁺, FLT3 -ITD ^- +TKD ^-, NPM1, NRAS and C-kit were significantly different between the two groups (all P < 0.05). When patients were divided into normal and abnormal karyotype group, it was found that the frequencies of FLT3- ITD ⁺, FLT3- TKD ⁺, NPM1, GATA2 and C-kit were significantly different between the two groups (all P < 0.05). The median overall survival (OS) of AML patients with FLT3 -TKD ⁺ (including FLT3- ITD ⁺+TKD ⁺) was longer than that of patients with FLT3- ITD ⁺ alone (P < 0.05). The OS and relapse-free survival (RFS) of AML patients with FLT3⁺+TET2⁺ were both shorter than those of patients with FLT3⁺+TET2^- (both P < 0.05).

Conclusion: The mutation frequencies of co-mutated genes are correlated with subtypes of FLT3, karyotype and AR. AML patients with FLT3 -TKD ⁺ have longer OS than patients with FLT3- ITD ⁺ alone, and patients with co-mutation of TET2 have shorter median OS and RFS.